Quick Answer
AYTU BIOPHARMA, INC reported Gross Profit of $45.83 million for the year ending 2025.
- AYTU BIOPHARMA, INC showed a decrease of -6.6% in Gross Profit from 2024 to 2025.
- This data is from AYTU BIOPHARMA, INC's annual report (Form 10-K), filed with the SEC on September 23, 2025.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $9.46 million | Q4 2020: $8.90 million | Q1 2021: -$452.0 thousand | Q3 2021: $12.46 million | Q4 2021: $12.30 million | Q1 2022: $12.69 million | Q3 2022: $18.03 million | Q4 2022: $17.29 million | Q1 2023: $12.74 million | Q3 2023: $13.04 million | Q4 2023: $14.60 million | Q1 2024: $10.36 million | Q3 2024: $11.99 million | Q4 2024: $10.79 million | Q1 2025: $12.81 million | Q3 2025: $9.19 million | Q4 2025: $9.62 million.
- Over the full 6 years of available data (2020 to 2025), AYTU BIOPHARMA, INC's Gross Profit has grown by 136.8%.
- Historical annual values: Fiscal year 2025: $45.83 million | Fiscal year 2024: $49.05 million | Fiscal year 2023: $66.63 million | Fiscal year 2022: $52.28 million | Fiscal year 2021: $29.20 million | Fiscal year 2020: $19.35 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: